QUARTERLY REPORT

Q3 2020 — Quarterly report

Q3 2020PDF · 32 pages144 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
È 	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED September 30, 2020
or
‘ 	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM 	TO
Commission File Number: 1-10864
UnitedHealth Group Incorporated
(Exact name of registrant as specified in its charter)
Delaware 	41-1321939
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
UnitedHealth Group Center
9900 Bren Road East
Minnetonka, Minnesota 	55343
(Address of principal executive offices) 	(Zip Code)
(952) 936-1300
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 	Trading Symbol(s) 	Name of each exchange on which registered
Common Stock, $.01 par value 	UNH 	NYSE
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing requirements for the past
90 days. 	Yes È 	No ‘
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be
submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for
such shorter period that the registrant was required to submit such files). 	Yes È 	No ‘
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a
smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,”
“accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act
Large accelerated filer 	È 	Accelerated filer ‘ 	Non-accelerated filer 	‘
Smaller reporting company 	‘ 	Emerging growth company ‘
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ‘
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Exchange Act). 	Yes ‘ 	No È
As of October 30, 2020, there were 948,820,710 shares of the registrant’s Common Stock, $.01 par value per share,
issued and outstanding.

-- 1 of 32 --

UNITEDHEALTH GROUP
Table of Contents
Page
Part I. Financial Information
Item 1. 	Financial Statements (unaudited) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1
Condensed Consolidated Balance Sheets as of September 30, 2020 and December 31, 2019 . . . 	1
Condensed Consolidated Statements of Operations for the Three and Nine Months Ended
September 30, 2020 and 2019 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2
Condensed Consolidated Statements of Comprehensive Income for the Three and Nine Months
Ended September 30, 2020 and 2019 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3
Condensed Consolidated Statements of Changes in Equity for the Three and Nine Months
Ended September 30, 2020 and 2019 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30,
2020 and 2019 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6
Notes to the Condensed Consolidated Financial Statements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	7
1. 	Basis of Presentation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	7
2. 	Investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	8
3. 	Fair Value . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	10
4. 	Medical Costs Payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	11
5. 	Short-Term Borrowings and Long-Term Debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	12
6. 	Dividends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	13
7. 	Commitments and Contingencies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	13
8. 	Segment Financial Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	15
Item 2. 	Management’s Discussion and Analysis of Financial Condition and Results of Operations . . . . 	17
Item 3. 	Quantitative and Qualitative Disclosures About Market Risk 	. . . . . . . . . . . . . . . . . . . . . . . . . . . 	27
Item 4. 	Controls and Procedures 	. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	27
Part II. Other Information
Item 1. 	Legal Proceedings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	28
Item 1A. 	Risk Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	28
Item 2. 	Unregistered Sales of Equity Securities and Use of Proceeds . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	28
Item 6. 	Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	29
Signatures 	. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	30

-- 2 of 32 --

PART I
ITEM 1. 	FINANCIAL STATEMENTS
UnitedHealth Group
Condensed Consolidated Balance Sheets
(Unaudited)
(in millions, except per share data)
September 30,
2020
December 31,
2019
Assets
Current assets:
Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 17,550 	$ 10,985
Short-term investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3,259 	3,260
Accounts receivable, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	12,171 	11,822
Other current receivables, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	13,231 	9,640
Assets under management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3,788 	3,076
Prepaid expenses and other current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,822 	3,851
Total current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	54,821 	42,634
Long-term investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	39,184 	37,209
Property, equipment and capitalized software, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	8,151 	8,704
Goodwill . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	68,088 	65,659
Other intangible assets, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	10,373 	10,349
Other assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	10,352 	9,334
Total assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$190,969 	$173,889
Liabilities, redeemable noncontrolling interests and equity
Current liabilities:
Medical costs payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 21,167 	$ 21,690
Accounts payable and accrued liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	21,173 	19,005
Short-term borrowings and current maturities of long-term debt . . . . . . . . . . . . . . . 	3,899 	3,870
Unearned revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,391 	2,622
Other current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	17,967 	14,595
Total current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	66,597 	61,782
Long-term debt, less current maturities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	39,895 	36,808
Deferred income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3,340 	2,993
Other liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	11,186 	10,144
Total liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	121,018 	111,727
Commitments and contingencies (Note 7) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Redeemable noncontrolling interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,847 	1,726
Equity:
Preferred stock, $0.001 par value—10 shares authorized; no shares issued or
outstanding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	— 	—
Common stock, $0.01 par value—3,000 shares authorized; 949 and 948 issued
and outstanding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	10 	9
Additional paid-in capital . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	— 	7
Retained earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	69,715 	61,178
Accumulated other comprehensive loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(4,494) 	(3,578)
Nonredeemable noncontrolling interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,873 	2,820
Total equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	68,104 	60,436
Total liabilities, redeemable noncontrolling interests and equity . . . . . . . . . . . . . . . . 	$190,969 	$173,889
See Notes to the Condensed Consolidated Financial Statements
1

-- 3 of 32 --

UnitedHealth Group
Condensed Consolidated Statements of Operations
(Unaudited)
Three Months Ended
September 30, Nine Months Ended
September 30,
(in millions, except per share data) 	2020 	2019 	2020 	2019
Revenues:
Premiums . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 50,863 $ 47,397 $ 150,897 $ 142,074
Products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	8,777 	7,546 	25,455 	23,971
Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	5,124 	4,942 	14,265 	13,756
Investment and other income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	351 	466 	1,057 	1,453
Total revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	65,115 	60,351 	191,674 	181,254
Operating costs:
Medical costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	41,636 	39,041 	117,314 	117,164
Operating costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	10,174 	8,960 	30,190 	25,892
Cost of products sold . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	7,935 	6,627 	23,123 	21,606
Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	719 	709 	2,159 	2,002
Total operating costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	60,464 	55,337 	172,786 	166,664
Earnings from operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,651 	5,014 	18,888 	14,590
Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(395) 	(449) 	(1,262) 	(1,267)
Earnings before income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,256 	4,565 	17,626 	13,323
Provision for income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,000) 	(936) 	(4,209) 	(2,752)
Net earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3,256 	3,629 	13,417 	10,571
Earnings attributable to noncontrolling interests . . . . . . . . . . . . . . . . . . . 	(84) 	(91) 	(226) 	(273)
Net earnings attributable to UnitedHealth Group common
shareholders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 3,172 $ 3,538 $ 13,191 $ 10,298
Earnings per share attributable to UnitedHealth Group common
shareholders:
Basic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 	3.34 $ 	3.73 $ 	13.90 $ 	10.82
Diluted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 	3.30 $ 	3.67 $ 	13.73 $ 	10.65
Basic weighted-average number of common shares outstanding . . . . 	950 	949 	949 	952
Dilutive effect of common share equivalents . . . . . . . . . . . . . . . . . . . . 	12 	14 	12 	15
Diluted weighted-average number of common shares
outstanding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	962 	963 	961 	967
Anti-dilutive shares excluded from the calculation of dilutive effect of
common share equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6 	12 	9 	10
See Notes to the Condensed Consolidated Financial Statements
2

-- 4 of 32 --

UnitedHealth Group
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
Three Months Ended
September 30, Nine Months Ended
September 30,
(in millions) 	2020 	2019 	2020 	2019
Net earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	3,256 	$ 	3,629 	$ 13,417 	$ 10,571
Other comprehensive income (loss):
Gross unrealized gains on investment securities during
the period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	148 	230 	919 	1,243
Income tax effect . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(37) 	(53) 	(214) 	(285)
Total unrealized gains, net of tax . . . . . . . . . . . . . . . 	111 	177 	705 	958
Gross reclassification adjustment for net realized gains
included in net earnings . . . . . . . . . . . . . . . . . . . . . . . . 	(21) 	(69) 	(50) 	(70)
Income tax effect . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	5 	16 	12 	16
Total reclassification adjustment, net of tax . . . . . . 	(16) 	(53) 	(38) 	(54)
Total foreign currency translation losses . . . . . . . . . . . . . 	(39) 	(560) 	(1,583) 	(453)
Other comprehensive income (loss) . . . . . . . . . . . . . . . . . . . . . 	56 	(436) 	(916) 	451
Comprehensive income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3,312 	3,193 	12,501 	11,022
Comprehensive income attributable to noncontrolling interests . . . 	(84) 	(91) 	(226) 	(273)
Comprehensive income attributable to UnitedHealth Group
common shareholders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	3,228 	$ 	3,102 	$ 12,275 	$ 10,749
See Notes to the Condensed Consolidated Financial Statements
3

-- 5 of 32 --

UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
Accumulated Other Comprehensive
Income (Loss)
Three months ended
September 30,
(in millions)
Common Stock Additional
Paid-In
Capital Retained
Earnings Net Unrealized Gains
on Investments
Foreign
Currency
Translation
Losses
Nonredeemable
Noncontrolling
Interests Total
Equity	Shares Amount
Balance at June 30, 2020 . . . . . . . 	950 $ 10 	$ 	388 $ 	67,776 $ 	1,161 	$ (5,711) $ 	2,891 $66,515
Net earnings . . . . . . . . . . . . . . . . . 	3,172 	62 	3,234
Other comprehensive income
(loss) . . . . . . . . . . . . . . . . . . . . . 	95 	(39) 	56
Issuances of common stock, and
related tax effects . . . . . . . . . . . 	2 	— 	321 	321
Share-based compensation . . . . . . 	131 	131
Common share repurchases . . . . . 	(3) 	— 	(805) 	(45) 	(850)
Cash dividends paid on common
shares ($1.25 per share) . . . . . . 	(1,188) 	(1,188)
Redeemable noncontrolling
interests fair value and other
adjustments . . . . . . . . . . . . . . . . 	(35) 	(35)
Acquisition and other adjustments
of nonredeemable
noncontrolling interests . . . . . . 	(8) 	(8)
Distribution to nonredeemable
noncontrolling interests . . . . . . 	(72) 	(72)
Balance at September 30, 2020 . . 	949 $ 10 	$ 	— $ 	69,715 $ 	1,256 	$ (5,750) $ 	2,873 $68,104
Balance at June 30, 2019 . . . . . . . 	948 $ 	9 	$ 	— $ 	56,367 $ 	516 	$ (3,789) $ 	2,751 $55,854
Net earnings . . . . . . . . . . . . . . . . . 	3,538 	82 	3,620
Other comprehensive income
(loss) . . . . . . . . . . . . . . . . . . . . . 	124 	(560) 	(436)
Issuances of common stock, and
related tax effects . . . . . . . . . . . 	2 	— 	277 	277
Share-based compensation . . . . . . 	130 	130
Common share repurchases . . . . . 	(3) 	— 	(415) 	(185) 	(600)
Cash dividends paid on common
shares ($1.08 per share) . . . . . . 	(1,024) 	(1,024)
Redeemable noncontrolling
interests fair value and other
adjustments . . . . . . . . . . . . . . . . 	8 	8
Acquisition and other adjustments
of nonredeemable
noncontrolling interests . . . . . . 	(7) 	(7)
Distribution to nonredeemable
noncontrolling interests . . . . . . 	(66) 	(66)
Balance at September 30, 2019 . . 	947 $ 	9 	$ 	— $ 	58,696 $ 	640 	$ (4,349) $ 	2,760 $57,756
See Notes to the Condensed Consolidated Financial Statements
4

-- 6 of 32 --

UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
Accumulated Other Comprehensive
Income (Loss)
Nine months ended
September 30,
(in millions)
Common Stock Additional
Paid-In
Capital Retained
Earnings
Net Unrealized Gains
(Losses) on
Investments
Foreign
Currency
Translation
Losses
Nonredeemable
Noncontrolling
Interests Total
Equity	Shares Amount
Balance at January 1, 2020 . . . . . . 	948 $ 	9 	$ 	7 $ 61,178 $ 	589 	$ (4,167) 	$ 	2,820 $60,436
Adjustment to adopt ASU
2016-13 . . . . . . . . . . . . . . . . . . . 	(28) 	(28)
Net earnings . . . . . . . . . . . . . . . . . 	13,191 	159 	13,350
Other comprehensive income
(loss) . . . . . . . . . . . . . . . . . . . . . 	667 	(1,583) 	(916)
Issuances of common stock, and
related tax effects . . . . . . . . . . . 	10 	1 	928 	929
Share-based compensation . . . . . . 	509 	509
Common share repurchases . . . . . 	(9) 	— 	(1,315) 	(1,226) 	(2,541)
Cash dividends paid on common
shares ($3.58 per share) . . . . . . 	(3,400) 	(3,400)
Redeemable noncontrolling
interests fair value and other
adjustments . . . . . . . . . . . . . . . . 	(129) 	(129)
Acquisition and other adjustments
of nonredeemable
noncontrolling interests . . . . . . 	42 	42
Distribution to nonredeemable
noncontrolling interests . . . . . . 	(148) 	(148)
Balance at September 30, 2020 . . 	949 $ 10 	$ 	— $ 69,715 $ 	1,256 	$ (5,750) 	$ 	2,873 $68,104
Balance at January 1, 2019 . . . . . . 	960 $ 10 	$ 	— $ 55,846 $ 	(264) $ (3,896) 	$ 	2,623 $54,319
Adjustment to adopt ASU
2016-02 . . . . . . . . . . . . . . . . . . . 	(13) 	(5) 	(18)
Net earnings . . . . . . . . . . . . . . . . . 	10,298 	196 	10,494
Other comprehensive income
(loss) . . . . . . . . . . . . . . . . . . . . . 	904 	(453) 	451
Issuances of common stock, and
related tax effects . . . . . . . . . . . 	8 	— 	438 	438
Share-based compensation . . . . . . 	521 	521
Common share repurchases . . . . . 	(21) 	(1) 	(573) 	(4,527) 	(5,101)
Cash dividends paid on common
shares ($3.06 per share) . . . . . . 	(2,908) 	(2,908)
Redeemable noncontrolling
interests fair value and other
adjustments . . . . . . . . . . . . . . . . 	(277) 	(277)
Acquisition and other adjustments
of nonredeemable
noncontrolling interests . . . . . . 	(109) 	157 	48
Distribution to nonredeemable
noncontrolling interests . . . . . . 	(211) 	(211)
Balance at September 30, 2019 . . 	947 $ 	9 	$ 	— $ 58,696 $ 	640 	$ (4,349) 	$ 	2,760 $57,756
See Notes to the Condensed Consolidated Financial Statements
5

-- 7 of 32 --

UnitedHealth Group
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Nine Months Ended
September 30,
(in millions) 	2020 	2019
Operating activities
Net earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 13,417 	$ 10,571
Noncash items:
Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,159 	2,002
Deferred income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	119 	177
Share-based compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	527 	525
Other, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	48 	(181)
Net change in other operating items, net of effects from acquisitions and changes in AARP
balances:
Accounts receivable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(194) 	957
Other assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(2,697) 	(2,181)
Medical costs payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(615) 	223
Accounts payable and other liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3,441 	105
Unearned revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(132) 	60
Cash flows from operating activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	16,073 	12,258
Investing activities
Purchases of investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(11,570) 	(13,386)
Sales of investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,887 	6,198
Maturities of investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	5,297 	5,160
Cash paid for acquisitions, net of cash assumed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(4,326) 	(8,200)
Purchases of property, equipment and capitalized software . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,477) 	(1,421)
Other, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(165) 	338
Cash flows used for investing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(7,354) 	(11,311)
Financing activities
Common share repurchases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(2,541) 	(5,101)
Cash dividends paid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(3,400) 	(2,908)
Proceeds from common stock issuances . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,206 	740
Repayments of long-term debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,500) 	(1,250)
(Repayments of) proceeds from short-term borrowings, net . . . . . . . . . . . . . . . . . . . . . . . . . 	(423) 	3,998
Proceeds from issuance of long-term debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,864 	5,444
Customer funds administered . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	249 	420
Other, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(449) 	(756)
Cash flows (used for) from financing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,994) 	587
Effect of exchange rate changes on cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . 	(160) 	(37)
Increase in cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6,565 	1,497
Cash and cash equivalents, beginning of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	10,985 	10,866
Cash and cash equivalents, end of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 17,550 	$ 12,363
See Notes to the Condensed Consolidated Financial Statements
6

-- 8 of 32 --

UnitedHealth Group
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
1. 	Basis of Presentation
UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and
“the Company”) is a diversified health care company dedicated to helping people live healthier lives and helping
make the health system work better for everyone.
Through its diversified family of businesses, the Company leverages core competencies in data and health
information, advanced technology and clinical expertise. These core competencies are deployed within two
distinct, but strategically aligned, business platforms: health benefits operating under UnitedHealthcare and
health services operating under Optum.
The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally
Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its
subsidiaries. The year-end condensed consolidated balance sheet was derived from audited financial statements,
but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S.
Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would
substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements.
Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated
Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and Supplementary Data”
in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the SEC
(2019 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring
adjustments necessary to present the interim financial statements fairly.
Use of Estimates
These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best
estimates and judgments. The Company’s most significant estimates include medical costs payable and goodwill.
Certain of these estimates require the application of complex assumptions and judgments, often because they
involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any
change in estimates is included in earnings in the period in which the estimate is adjusted.
Revenue from Products
For the three and nine months ended September 30, 2020, the Company recognized revenue and cost of products
sold for retail pharmacy co-payments related to its OptumRx business. Revenue recognized in prior periods
related to retail pharmacy transactions excludes the member’s applicable co-payment. There was no impact on
earnings from operations, net earnings, earnings per share or total equity.
Recently Adopted Accounting Standards
In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU)
No. 2016-13, “Financial Instruments—Credit Losses (Topic 326)” (ASU 2016-13). ASU 2016-13 requires the
use of the current expected credit loss impairment model to develop an estimate of expected credit losses for
certain financial assets. ASU 2016-13 also requires expected credit losses on available-for-sale debt securities to
be recognized through an allowance for credit losses and revises certain disclosure requirements. The Company
adopted ASU 2016-13 on January 1, 2020 using a cumulative effect upon adoption approach. The adoption of
ASU 2016-13 was immaterial to the Company’s consolidated balance sheet, results of operations, equity and
cash flows.
7

-- 9 of 32 --

Under the current expected credit loss impairment model, the Company evaluates an available-for-sale debt
security for credit-related impairment by considering the present value of expected cash flows relative to a
security’s amortized cost, the extent to which fair value is less than amortized cost, the financial condition and
near-term prospects of the issuer and specific events or circumstances that may influence the operations of the
issuer. Credit-related impairments are recorded as an allowance, with an offset to investment and other income.
Non-credit related impairments are recorded through other comprehensive income. If the Company intends to
sell an impaired security, or will likely be required to sell a security before recovery of the entire amortized cost,
the entire impairment is included in net earnings.
The Company has determined that there have been no other recently adopted or issued accounting standards that
had, or will have, a material impact on its Condensed Consolidated Financial Statements.
2. 	Investments
A summary of debt securities by major security type is as follows:
(in millions) Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses Fair
Value
September 30, 2020
Debt securities—available-for-sale:
U.S. government and agency obligations . . . . . . . . . . . . . . . . . 	$ 3,374 	$ 160 	$ — 	$ 3,534
State and municipal obligations . . . . . . . . . . . . . . . . . . . . . . . . 	6,311 	377 	(4) 	6,684
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	18,461 	778 	(35) 	19,204
U.S. agency mortgage-backed securities . . . . . . . . . . . . . . . . . 	6,523 	270 	(3) 	6,790
Non-U.S. agency mortgage-backed securities . . . . . . . . . . . . . 	2,033 	98 	(6) 	2,125
Total debt securities—available-for-sale . . . . . . . . . . . . . . . . . . . . . 	36,702 	1,683 	(48) 	38,337
Debt securities—held-to-maturity:
U.S. government and agency obligations . . . . . . . . . . . . . . . . . 	422 	7 	— 	429
State and municipal obligations . . . . . . . . . . . . . . . . . . . . . . . . 	31 	2 	— 	33
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	245 	1 	— 	246
Total debt securities—held-to-maturity . . . . . . . . . . . . . . . . . . . . . . 	698 	10 	— 	708
Total debt securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$37,400 	$1,693 	$(48) 	$39,045
December 31, 2019
Debt securities—available-for-sale:
U.S. government and agency obligations . . . . . . . . . . . . . . . . . 	$ 3,502 	$ 	55 	$ (4) 	$ 3,553
State and municipal obligations . . . . . . . . . . . . . . . . . . . . . . . . 	5,680 	251 	(5) 	5,926
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	17,910 	343 	(11) 	18,242
U.S. agency mortgage-backed securities . . . . . . . . . . . . . . . . . 	6,425 	109 	(6) 	6,528
Non-U.S. agency mortgage-backed securities . . . . . . . . . . . . . 	1,811 	37 	(3) 	1,845
Total debt securities—available-for-sale . . . . . . . . . . . . . . . . . . . . . 	35,328 	795 	(29) 	36,094
Debt securities—held-to-maturity:
U.S. government and agency obligations . . . . . . . . . . . . . . . . . 	402 	2 	— 	404
State and municipal obligations . . . . . . . . . . . . . . . . . . . . . . . . 	32 	2 	— 	34
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	538 	— 	(1) 	537
Total debt securities—held-to-maturity . . . . . . . . . . . . . . . . . . . . . . 	972 	4 	(1) 	975
Total debt securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$36,300 	$ 799 	$(30) 	$37,069
8

-- 10 of 32 --

The Company held $2.1 billion and $2.0 billion of equity securities as of September 30, 2020 and December 31,
2019, respectively. The Company’s investments in equity securities primarily consist of employee savings plan
related investments and shares of Brazilian real denominated fixed-income funds with readily determinable fair
values. Additionally, the Company’s investments included $1.3 billion and $1.4 billion of equity method
investments in operating businesses in the health care sector as of September 30, 2020 and December 31, 2019,
respectively. The allowance for credit losses on held-to-maturity securities at September 30, 2020 was not
material.
The amortized cost and fair value of debt securities as of September 30, 2020, by contractual maturity, were as
follows:
Available-for-Sale 	Held-to-Maturity
(in millions) Amortized
Cost Fair
Value Amortized
Cost Fair
Value
Due in one year or less . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	3,388 	$ 	3,407 	$ 	400 	$ 	401
Due after one year through five years . . . . . . . . . . . . . . . . . . . . . . . . . . . 	11,253 	11,678 	246 	252
Due after five years through ten years . . . . . . . . . . . . . . . . . . . . . . . . . . 	9,179 	9,826 	30 	31
Due after ten years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,326 	4,511 	22 	24
U.S. agency mortgage-backed securities . . . . . . . . . . . . . . . . . . . . . . . . 	6,523 	6,790 	— 	—
Non-U.S. agency mortgage-backed securities . . . . . . . . . . . . . . . . . . . . 	2,033 	2,125 	— 	—
Total debt securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	36,702 	$ 	38,337 	$ 	698 	$ 	708
The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length
of time that individual securities have been in a continuous unrealized loss position were as follows:
Less Than 12 Months 12 Months or Greater 	Total
(in millions) Fair
Value
Gross
Unrealized
Losses Fair
Value
Gross
Unrealized
Losses Fair
Value
Gross
Unrealized
Losses
September 30, 2020
Debt securities—available-for-sale:
State and municipal obligations . . . . . . . . . . . . . . $ 	366 	$ 	(4) 	$ 	— 	$ 	— 	$ 	366 	$ 	(4)
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . 	2,314 	(30) 	400 	(5) 	2,714 	(35)
U.S. agency mortgage-backed securities . . . . . . . 	687 	(3) 	— 	— 	687 	(3)
Non-U.S. agency mortgage-backed securities . . . 	278 	(3) 	55 	(3) 	333 	(6)
Total debt securities—available-for-sale . . . . . . . . . . . $ 	3,645 	$ 	(40) 	$ 	455 	$ 	(8) 	$ 	4,100 	$ 	(48)
December 31, 2019
Debt securities—available-for-sale:
U.S. government and agency obligations . . . . . . . $ 	616 	$ 	(4) 	$ 	— 	$ 	— 	$ 	616 	$ 	(4)
State and municipal obligations . . . . . . . . . . . . . . 	440 	(5) 	— 	— 	440 	(5)
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . 	1,903 	(7) 	740 	(4) 	2,643 	(11)
U.S. agency mortgage-backed securities . . . . . . . 	657 	(3) 	333 	(3) 	990 	(6)
Non-U.S. agency mortgage-backed securities . . . 	406 	(3) 	— 	— 	406 	(3)
Total debt securities—available-for-sale . . . . . . . . . . . $ 	4,022 	$ 	(22) 	$ 1,073 	$ 	(7) 	$ 	5,095 	$ 	(29)
The Company’s unrealized losses from debt securities as of September 30, 2020 were generated from
approximately 3,000 positions out of a total of 34,000 positions. The Company believes that it will collect the
timely principal and interest due on its debt securities that have an amortized cost in excess of fair value. The
unrealized losses were primarily caused by interest rate increases and not by unfavorable changes in the credit
quality associated with these securities that impacted our assessment on collectability of principal and interest. At
each reporting period, the Company evaluates available-for-sale debt securities for any credit-related impairment
when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash
9

-- 11 of 32 --

flows, the underlying credit quality and credit ratings of the issuers, and the potential economic impacts of
COVID-19 on the issuers, noting no significant credit deterioration since purchase. As of September 30, 2020,
the Company did not have the intent to sell any of the available-for-sale debt securities in an unrealized loss
position. Therefore, the Company believes these losses to be temporary. The allowance for credit losses on
available-for-sale debt securities at September 30, 2020 was not material.
3. 	Fair Value
Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or
have fair values disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and
liabilities are classified into one of three levels of a hierarchy defined by GAAP.
For a description of the methods and assumptions that are used to estimate the fair value and determine the fair
value hierarchy classification of each class of financial instrument, see Note 4 of Notes to the Consolidated
Financial Statements in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2019 10-K.
The following table presents a summary of fair value measurements by level and carrying values for items
measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)
Quoted Prices
in Active
Markets
(Level 1)
Other
Observable
Inputs
(Level 2)
Unobservable
Inputs
(Level 3)
Total
Fair and
Carrying
Value
September 30, 2020
Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	17,472 	$ 	78 	$ 	— 	$ 	17,550
Debt securities—available-for-sale:
U.S. government and agency obligations . . . . . . . . . . . . . 	3,336 	198 	— 	3,534
State and municipal obligations . . . . . . . . . . . . . . . . . . . . . 	— 	6,684 	— 	6,684
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	44 	18,881 	279 	19,204
U.S. agency mortgage-backed securities . . . . . . . . . . . . . . 	— 	6,790 	— 	6,790
Non-U.S. agency mortgage-backed securities . . . . . . . . . . 	— 	2,125 	— 	2,125
Total debt securities—available-for-sale . . . . . . . . . . . . . . . . . . 	3,380 	34,678 	279 	38,337
Equity securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,593 	30 	— 	1,623
Assets under management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,690 	2,050 	48 	3,788
Total assets at fair value . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	24,135 	$ 	36,836 	$ 	327 	$ 	61,298
Percentage of total assets at fair value . . . . . . . . . . . . . . . . . . . . 	39% 	60% 	1% 	100%
December 31, 2019
Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	10,837 	$ 	148 	$ 	— 	$ 	10,985
Debt securities—available-for-sale:
U.S. government and agency obligations . . . . . . . . . . . . . 	3,369 	184 	— 	3,553
State and municipal obligations . . . . . . . . . . . . . . . . . . . . . 	— 	5,926 	— 	5,926
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	70 	17,923 	249 	18,242
U.S. agency mortgage-backed securities . . . . . . . . . . . . . . 	— 	6,528 	— 	6,528
Non-U.S. agency mortgage-backed securities . . . . . . . . . . 	— 	1,845 	— 	1,845
Total debt securities—available-for-sale . . . . . . . . . . . . . . . . . . 	3,439 	32,406 	249 	36,094
Equity securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,734 	22 	— 	1,756
Assets under management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,123 	1,918 	35 	3,076
Total assets at fair value . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	17,133 	$ 	34,494 	$ 	284 	$ 	51,911
Percentage of total assets at fair value . . . . . . . . . . . . . . . . . . . . 	33% 	66% 	1% 	100%
10

-- 12 of 32 --

There were no transfers in or out of Level 3 financial assets or liabilities during the nine months ended
September 30, 2020 or 2019.
The following table presents a summary of fair value measurements by level and carrying values for certain
financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance
Sheets:
(in millions)
Quoted Prices
in Active
Markets
(Level 1)
Other
Observable
Inputs
(Level 2)
Unobservable
Inputs
(Level 3)
Total
Fair
Value
Total
Carrying
Value
September 30, 2020
Debt securities—held-to-maturity . . . . . . . . . . . . . . 	$ 	531 	$ 	99 	$ 	78 	$ 	708 	$ 	698
Long-term debt and other financing obligations . . . 	$ 	— 	$ 51,785 	$ 	— 	$ 51,785 	$ 43,794
December 31, 2019
Debt securities—held-to-maturity . . . . . . . . . . . . . . 	$ 	541 	$ 	181 	$ 	253 	$ 	975 	$ 	972
Long-term debt and other financing obligations . . . 	$ 	— 	$ 45,078 	$ 	— 	$ 45,078 	$ 40,278
Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a
nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company
records an impairment. There were no significant fair value adjustments for these assets and liabilities recorded
during either the nine months ended September 30, 2020 or 2019.
4. 	Medical Costs Payable
The following table shows the components of the change in medical costs payable for the nine months ended
September 30:
(in millions) 	2020 	2019
Medical costs payable, beginning of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	21,690 	$ 	19,891
Acquisitions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	186 	868
Reported medical costs:
Current year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	118,114 	117,624
Prior years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(800) 	(460)
Total reported medical costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	117,314 	117,164
Medical payments:
Payments for current year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(98,548) 	(99,487)
Payments for prior years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(19,475) 	(17,497)
Total medical payments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(118,023) 	(116,984)
Medical costs payable, end of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	21,167 	$ 	20,939
For the nine months ended September 30, 2020, prior years medical cost reserve development was primarily
driven by lower than expected health system utilization. For the nine months ended September 30, 2019, the prior
years medical cost reserve development included no individual factors that were significant. Medical costs
payable included reserves for claims incurred by insured customers but not yet reported to the Company of
$14.7 billion and $13.8 billion at September 30, 2020 and December 31, 2019, respectively.
11

-- 13 of 32 --

5. 	Short-Term Borrowings and Long-Term Debt
Short-term borrowings and senior unsecured long-term debt consisted of the following:
September 30, 2020 	December 31, 2019
(in millions, except percentages) Par
Value Carrying
Value Fair
Value Par
Value Carrying
Value Fair
Value
Commercial paper . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	— 	$ 	— 	$ 	— 	$ 	400 	$ 	400 	$ 	400
2.700% notes due July 2020 . . . . . . . . . . . . . . . . . . . . . . . . . . 	— 	— 	— 	1,500 	1,499 	1,506
Floating rate notes due October 2020 . . . . . . . . . . . . . . . . . . 	300 	300 	300 	300 	300 	300
3.875% notes due October 2020 . . . . . . . . . . . . . . . . . . . . . . 	450 	450 	451 	450 	450 	455
1.950% notes due October 2020 . . . . . . . . . . . . . . . . . . . . . . 	900 	900 	901 	900 	899 	900
4.700% notes due February 2021 . . . . . . . . . . . . . . . . . . . . . . 	400 	403 	402 	400 	403 	410
2.125% notes due March 2021 . . . . . . . . . . . . . . . . . . . . . . . . 	750 	749 	756 	750 	749 	753
Floating rate notes due June 2021 . . . . . . . . . . . . . . . . . . . . . 	350 	350 	351 	350 	349 	350
3.150% notes due June 2021 . . . . . . . . . . . . . . . . . . . . . . . . . 	400 	400 	408 	400 	399 	407
3.375% notes due November 2021 . . . . . . . . . . . . . . . . . . . . 	500 	509 	513 	500 	501 	512
2.875% notes due December 2021 . . . . . . . . . . . . . . . . . . . . . 	750 	765 	774 	750 	753 	765
2.875% notes due March 2022 . . . . . . . . . . . . . . . . . . . . . . . . 	1,100 	1,115 	1,133 	1,100 	1,087 	1,121
3.350% notes due July 2022 . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,000 	998 	1,054 	1,000 	998 	1,036
2.375% notes due October 2022 . . . . . . . . . . . . . . . . . . . . . . 	900 	897 	937 	900 	896 	911
0.000% notes due November 2022 . . . . . . . . . . . . . . . . . . . . 	15 	13 	14 	15 	13 	14
2.750% notes due February 2023 . . . . . . . . . . . . . . . . . . . . . . 	625 	646 	656 	625 	624 	638
2.875% notes due March 2023 . . . . . . . . . . . . . . . . . . . . . . . . 	750 	793 	794 	750 	770 	770
3.500% notes due June 2023 . . . . . . . . . . . . . . . . . . . . . . . . . 	750 	748 	811 	750 	747 	786
3.500% notes due February 2024 . . . . . . . . . . . . . . . . . . . . . . 	750 	746 	825 	750 	746 	792
2.375% notes due August 2024 . . . . . . . . . . . . . . . . . . . . . . . 	750 	747 	799 	750 	747 	760
3.750% notes due July 2025 . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,000 	1,992 	2,283 	2,000 	1,990 	2,161
3.700% notes due December 2025 . . . . . . . . . . . . . . . . . . . . . 	300 	298 	343 	300 	298 	325
1.250% notes due January 2026 . . . . . . . . . . . . . . . . . . . . . . . 	500 	496 	513 	— 	— 	—
3.100% notes due March 2026 . . . . . . . . . . . . . . . . . . . . . . . . 	1,000 	996 	1,118 	1,000 	996 	1,048
3.450% notes due January 2027 . . . . . . . . . . . . . . . . . . . . . . . 	750 	746 	853 	750 	746 	804
3.375% notes due April 2027 . . . . . . . . . . . . . . . . . . . . . . . . . 	625 	620 	713 	625 	620 	667
2.950% notes due October 2027 . . . . . . . . . . . . . . . . . . . . . . 	950 	940 	1,060 	950 	939 	988
3.850% notes due June 2028 . . . . . . . . . . . . . . . . . . . . . . . . . 	1,150 	1,143 	1,357 	1,150 	1,142 	1,269
3.875% notes due December 2028 . . . . . . . . . . . . . . . . . . . . . 	850 	843 	1,010 	850 	843 	941
2.875% notes due August 2029 . . . . . . . . . . . . . . . . . . . . . . . 	1,000 	1,104 	1,115 	1,000 	993 	1,029
2.000% notes due May 2030 . . . . . . . . . . . . . . . . . . . . . . . . . 	1,250 	1,233 	1,310 	— 	— 	—
4.625% notes due July 2035 . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,000 	992 	1,317 	1,000 	992 	1,215
5.800% notes due March 2036 . . . . . . . . . . . . . . . . . . . . . . . . 	850 	839 	1,231 	850 	838 	1,129
6.500% notes due June 2037 . . . . . . . . . . . . . . . . . . . . . . . . . 	500 	492 	778 	500 	492 	712
6.625% notes due November 2037 . . . . . . . . . . . . . . . . . . . . 	650 	641 	1,027 	650 	641 	940
6.875% notes due February 2038 . . . . . . . . . . . . . . . . . . . . . . 	1,100 	1,077 	1,772 	1,100 	1,076 	1,631
3.500% notes due August 2039 . . . . . . . . . . . . . . . . . . . . . . . 	1,250 	1,241 	1,436 	1,250 	1,241 	1,313
2.750% notes due May 2040 . . . . . . . . . . . . . . . . . . . . . . . . . 	1,000 	964 	1,057 	— 	— 	—
5.700% notes due October 2040 . . . . . . . . . . . . . . . . . . . . . . 	300 	296 	438 	300 	296 	396
5.950% notes due February 2041 . . . . . . . . . . . . . . . . . . . . . . 	350 	346 	525 	350 	345 	475
4.625% notes due November 2041 . . . . . . . . . . . . . . . . . . . . 	600 	589 	787 	600 	589 	716
4.375% notes due March 2042 . . . . . . . . . . . . . . . . . . . . . . . . 	502 	485 	639 	502 	484 	580
3.950% notes due October 2042 . . . . . . . . . . . . . . . . . . . . . . 	625 	608 	760 	625 	607 	688
4.250% notes due March 2043 . . . . . . . . . . . . . . . . . . . . . . . . 	750 	735 	949 	750 	735 	856
4.750% notes due July 2045 . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,000 	1,973 	2,730 	2,000 	1,973 	2,463
4.200% notes due January 2047 . . . . . . . . . . . . . . . . . . . . . . . 	750 	738 	950 	750 	738 	861
4.250% notes due April 2047 . . . . . . . . . . . . . . . . . . . . . . . . . 	725 	717 	923 	725 	717 	839
3.750% notes due October 2047 . . . . . . . . . . . . . . . . . . . . . . 	950 	934 	1,130 	950 	934 	1,023
4.250% notes due June 2048 . . . . . . . . . . . . . . . . . . . . . . . . . 	1,350 	1,330 	1,721 	1,350 	1,330 	1,569
4.450% notes due December 2048 . . . . . . . . . . . . . . . . . . . . . 	1,100 	1,086 	1,457 	1,100 	1,086 	1,316
3.700% notes due August 2049 . . . . . . . . . . . . . . . . . . . . . . . 	1,250 	1,235 	1,496 	1,250 	1,235 	1,344
2.900% notes due May 2050 . . . . . . . . . . . . . . . . . . . . . . . . . 	1,250 	1,208 	1,318 	— 	— 	—
3.875% notes due August 2059 . . . . . . . . . . . . . . . . . . . . . . . 	1,250 	1,228 	1,529 	1,250 	1,228 	1,350
3.125% notes due May 2060 . . . . . . . . . . . . . . . . . . . . . . . . . 	1,000 	968 	1,073 	— 	— 	—
Total short-term borrowings and long-term debt . . . . . . . . . . 	$ 42,917 	$ 42,662 	$ 50,597 	$ 39,817 	$ 39,474 	$ 44,234
12

-- 14 of 32 --

The Company’s long-term debt obligations also included $1.1 billion and $1.2 billion of other financing
obligations, of which $347 million and $322 million were classified as current as of September 30, 2020 and
December 31, 2019, respectively.
Commercial Paper and Bank Credit Facilities
Commercial paper consists of short-duration, senior unsecured debt privately placed on a discount basis through
broker-dealers.
The Company has $4.4 billion five-year, $4.4 billion three-year and $3.8 billion 364-day revolving bank credit
facilities with 25 banks, which mature in December 2024, December 2022 and December 2020, respectively.
These facilities provide liquidity support for the Company’s commercial paper program and are available for
general corporate purposes. As of September 30, 2020, no amounts had been drawn on any of the bank credit
facilities. The annual interest rates, which are variable based on term, are calculated based on the London
Interbank Offered Rate (LIBOR) plus a credit spread based on the Company’s senior unsecured credit ratings. If
amounts had been drawn on the bank credit facilities as of September 30, 2020, annual interest rates would have
ranged from 0.8% to 1%.
Debt Covenants
The Company’s bank credit facilities contain various covenants, including covenants requiring the Company to
maintain a defined debt to debt-plus-shareholders’ equity ratio of not more than 60%. The Company was in
compliance with its debt covenants as of September 30, 2020.
6. 	Dividends
In June 2020, the Company’s Board of Directors increased the Company’s quarterly cash dividend to
shareholders to an annual rate of $5.00 compared to $4.32 per share, which the Company had paid since June
2019. Declaration and payment of future quarterly dividends is at the discretion of the Board and may be adjusted
as business needs or market conditions change.
The following table provides details of the Company’s 2020 dividend payments:
Payment Date 	Amount per Share 	Total Amount Paid
(in millions)
March 24 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	1.08 	$ 	1,024
June 30 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1.25 	1,188
September 22 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1.25 	1,188
7. 	Commitments and Contingencies
Legal Matters
Because of the nature of its businesses, the Company is frequently made party to a variety of legal actions and
regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy
organizations, customers and regulators, relating to the Company’s businesses, including management and
administration of health benefit plans and other services. These matters include medical malpractice,
employment, intellectual property, antitrust, privacy and contract claims and claims related to health care benefits
coverage and other business practices.
The Company records liabilities for its estimates of probable costs resulting from these matters where
appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently
difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may
13

-- 15 of 32 --

involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy;
involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could
result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or
ranges of losses for those matters where there is a reasonable possibility or it is probable that a loss may be
incurred.
Government Investigations, Audits and Reviews
The Company has been involved or is currently involved in various governmental investigations, audits and
reviews. These include routine, regular and special investigations, audits and reviews by the Centers for
Medicare and Medicaid Services (CMS), state insurance and health and welfare departments, state attorneys
general, the Office of the Inspector General, the Office of Personnel Management, the Office of Civil Rights, the
Government Accountability Office, the Federal Trade Commission, U.S. Congressional committees, the U.S.
Department of Justice, the SEC, the Internal Revenue Service, the U.S. Drug Enforcement Administration, the
U.S. Department of Labor, the Federal Deposit Insurance Corporation, the Defense Contract Audit Agency and
other governmental authorities. Similarly, our international businesses are also subject to investigations, audits
and reviews by applicable foreign governments, including South American and other non-U.S. governmental
authorities. Certain of the Company’s businesses have been reviewed or are currently under review, including
for, among other matters, compliance with coding and other requirements under the Medicare risk-adjustment
model. CMS has selected certain of the Company’s local plans for risk adjustment data validation (RADV) audits
to validate the coding practices of and supporting documentation maintained by health care providers and such
audits may result in retrospective adjustments to payments made to the Company’s health plans.
On February 14, 2017, the Department of Justice (DOJ) announced its decision to pursue certain claims within a
lawsuit initially asserted against the Company and filed under seal by a whistleblower in 2011. The
whistleblower’s complaint, which was unsealed on February 15, 2017, alleges that the Company made improper
risk adjustment submissions and violated the False Claims Act. On February 12, 2018, the court granted in part
and denied in part the Company’s motion to dismiss. In May 2018, DOJ moved to dismiss the Company’s
counterclaims, which were filed in March 2018, and moved for partial summary judgment. In March 2019, the
court denied the government’s motion for partial summary judgment and dismissed the Company’s
counterclaims without prejudice. The Company cannot reasonably estimate the outcome that may result from this
matter given its procedural status.
14

-- 16 of 32 --

8. 	Segment Financial Information
The Company’s four reportable segments are UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. For more
information on the Company’s segments see Part I, Item I, “Business” and Note 14 of Notes to the Consolidated Financial
Statements in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2019 10-K.
The following tables present reportable segment financial information:
Optum
(in millions) 	UnitedHealthcare OptumHealth OptumInsight OptumRx Optum
Eliminations 	Optum Corporate and
Eliminations Consolidated
Three Months Ended
September 30, 2020
Revenues—unaffiliated
customers:
Premiums . . . . . . . . . . . . 	$ 	48,121 	$ 	2,742 	$ 	— 	$ 	— 	$ 	— 	$ 	2,742 	$ 	— 	$ 50,863
Products . . . . . . . . . . . . . 	— 	10 	34 	8,733 	— 	8,777 	— 	8,777
Services . . . . . . . . . . . . . 	2,075 	1,834 	974 	241 	— 	3,049 	— 	5,124
Total revenues—unaffiliated
customers . . . . . . . . . . . . 	50,196 	4,586 	1,008 	8,974 	— 	14,568 	— 	64,764
Total revenues—affiliated
customers . . . . . . . . . . . . 	— 	5,748 	1,755 	13,102 	(424) 	20,181 	(20,181) 	—
Investment and other
income . . . . . . . . . . . . . . 	177 	165 	4 	5 	— 	174 	— 	351
Total revenues . . . . . . . . . . 	$ 	50,373 	$ 	10,499 	$ 	2,767 	$ 22,081 	$ 	(424) $ 34,923 	$ (20,181) $ 65,115
Earnings from operations . 	$ 	2,068 	$ 	835 	$ 	785 	$ 	963 	$ 	— 	$ 	2,583 	$ 	— 	$ 	4,651
Interest expense . . . . . . . . . 	— 	— 	— 	— 	— 	— 	(395) 	(395)
Earnings before income
taxes . . . . . . . . . . . . . . . . 	$ 	2,068 	$ 	835 	$ 	785 	$ 	963 	$ 	— 	$ 	2,583 	$ 	(395) $ 	4,256
Three Months Ended
September 30, 2019
Revenues—unaffiliated
customers:
Premiums . . . . . . . . . . . . 	$ 	45,557 	$ 	1,840 	$ 	— 	$ 	— 	$ 	— 	$ 	1,840 	$ 	— 	$ 47,397
Products . . . . . . . . . . . . . 	— 	6 	29 	7,511 	— 	7,546 	— 	7,546
Services . . . . . . . . . . . . . 	2,274 	1,487 	988 	193 	— 	2,668 	— 	4,942
Total revenues—unaffiliated
customers . . . . . . . . . . . . 	47,831 	3,333 	1,017 	7,704 	— 	12,054 	— 	59,885
Total revenues—affiliated
customers . . . . . . . . . . . . 	— 	4,630 	1,594 	10,734 	(441) 	16,517 	(16,517) 	—
Investment and other
income . . . . . . . . . . . . . . 	274 	170 	6 	16 	— 	192 	— 	466
Total revenues . . . . . . . . . . 	$ 	48,105 	$ 	8,133 	$ 	2,617 	$ 18,454 	$ 	(441) $ 28,763 	$ (16,517) $ 60,351
Earnings from operations . 	$ 	2,655 	$ 	748 	$ 	632 	$ 	979 	$ 	— 	$ 	2,359 	$ 	— 	$ 	5,014
Interest expense . . . . . . . . . 	— 	— 	— 	— 	— 	— 	(449) 	(449)
Earnings before income
taxes . . . . . . . . . . . . . . . . 	$ 	2,655 	$ 	748 	$ 	632 	$ 	979 	$ 	— 	$ 	2,359 	$ 	(449) $ 	4,565
15

-- 17 of 32 --

Optum
(in millions) 	UnitedHealthcare OptumHealth OptumInsight OptumRx Optum
Eliminations 	Optum Corporate and
Eliminations Consolidated
Nine Months Ended
September 30, 2020
Revenues—unaffiliated
customers:
Premiums . . . . . . . . . . . . 	$ 	143,753 	$ 	7,144 	$ 	— 	$ 	— 	$ 	— 	$ 	7,144 	$ 	— 	$ 150,897
Products . . . . . . . . . . . . . 	— 	26 	90 	25,339 	— 	25,455 	— 	25,455
Services . . . . . . . . . . . . . 	6,248 	4,607 	2,629 	781 	— 	8,017 	— 	14,265
Total revenues—unaffiliated
customers . . . . . . . . . . . . 	150,001 	11,777 	2,719 	26,120 	— 	40,616 	— 	190,617
Total revenues—affiliated
customers . . . . . . . . . . . . 	— 	16,623 	5,140 	38,843 	(1,275) 	59,331 	(59,331) 	—
Investment and other
income . . . . . . . . . . . . . . 	547 	430 	34 	46 	— 	510 	— 	1,057
Total revenues . . . . . . . . . . 	$ 	150,548 	$ 	28,830 	$ 	7,893 	$ 65,009 	$ (1,275) $ 100,457 	$ (59,331) $ 191,674
Earnings from operations . 	$ 	11,963 	$ 	2,388 	$ 	1,882 	$ 2,655 	$ 	— 	$ 	6,925 	$ 	— 	$ 18,888
Interest expense . . . . . . . . . 	— 	— 	— 	— 	— 	— 	(1,262) 	(1,262)
Earnings before income
taxes . . . . . . . . . . . . . . . . 	$ 	11,963 	$ 	2,388 	$ 	1,882 	$ 2,655 	$ 	— 	$ 	6,925 	$ 	(1,262) $ 17,626
Nine Months Ended
September 30, 2019
Revenues—unaffiliated
customers:
Premiums . . . . . . . . . . . . 	$ 	138,088 	$ 	3,986 	$ 	— 	$ 	— 	$ 	— 	$ 	3,986 	$ 	— 	$ 142,074
Products . . . . . . . . . . . . . 	— 	23 	74 	23,874 	— 	23,971 	— 	23,971
Services . . . . . . . . . . . . . 	6,603 	4,131 	2,532 	490 	— 	7,153 	— 	13,756
Total revenues—unaffiliated
customers . . . . . . . . . . . . 	144,691 	8,140 	2,606 	24,364 	— 	35,110 	— 	179,801
Total revenues—affiliated
customers . . . . . . . . . . . . 	— 	13,366 	4,522 	30,786 	(1,181) 	47,493 	(47,493) 	—
Investment and other
income . . . . . . . . . . . . . . 	904 	488 	17 	44 	— 	549 	— 	1,453
Total revenues . . . . . . . . . . 	$ 	145,595 	$ 	21,994 	$ 	7,145 	$ 55,194 	$ (1,181) $ 83,152 	$ (47,493) $ 181,254
Earnings from operations . 	$ 	8,251 	$ 	2,062 	$ 	1,589 	$ 2,688 	$ 	— 	$ 	6,339 	$ 	— 	$ 14,590
Interest expense . . . . . . . . . 	— 	— 	— 	— 	— 	— 	(1,267) 	(1,267)
Earnings before income
taxes . . . . . . . . . . . . . . . . 	$ 	8,251 	$ 	2,062 	$ 	1,589 	$ 2,688 	$ 	— 	$ 	6,339 	$ 	(1,267) $ 13,323
16

-- 18 of 32 --

ITEM 2. 	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
The following discussion should be read together with the accompanying Condensed Consolidated Financial
Statements and Notes and with our 2019 10-K, including the Consolidated Financial Statements and Notes in
Part II, Item 8, “Financial Statements and Supplementary Data” in that report. Unless the context indicates
otherwise, references to the terms “UnitedHealth Group,” “we,” “our” or “us” used throughout this
Management’s Discussion and Analysis of Financial Condition and Results of Operations refer to UnitedHealth
Group Incorporated and its consolidated subsidiaries.
Readers are cautioned that the statements, estimates, projections or outlook contained in this Management’s
Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding
financial prospects, economic conditions, trends and uncertainties contained in this Item 2, may constitute
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995
(PSLRA). These forward-looking statements involve risks and uncertainties that may cause our actual results to
differ materially from the results discussed or implied in the forward-looking statements. A description of some
of the risks and uncertainties is set forth in Part I, Item 1A, “Risk Factors” in our 2019 10-K and in the discussion
below.
EXECUTIVE OVERVIEW
General
UnitedHealth Group is a diversified health care company dedicated to helping people live healthier lives and
helping make the health system work better for everyone. Through our diversified family of businesses, we
leverage core competencies in data and health information; advanced technology; and clinical expertise, focused
on improving health outcomes, lowering health care costs and creating a better experience for patients, their
caregivers and physicians. These core competencies are deployed within our two distinct, but strategically
aligned, business platforms: health benefits operating under UnitedHealthcare and health services operating
under Optum.
Further information on our business is presented in Part I, Item 1, “Business” and Part II, Item 7, “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” in our 2019 10-K and additional
information on our segments can be found in this Item 2 and in Note 8 of Notes to the Condensed Consolidated
Financial Statements included in Part I, Item 1 of this report.
COVID-19 Trends and Uncertainties
The COVID-19 pandemic continues to evolve and the ultimate impact on our business, results of operations,
financial condition and cash flows remains uncertain and difficult to predict. During the second quarter, the
global health system experienced unprecedented levels of care deferral, which impacted all of our businesses. As
the pandemic advanced, access to and demand for care was most constrained from mid-March through April,
began to recover in May and June and restored to near normal seasonal levels in the third quarter. The temporary
deferral of care may cause care patterns to moderately exceed normal baselines in future periods as utilization of
health system capacity continues to increase. From time to time, health system capacity may be subject to
possible increased volatility due to the pandemic. Specific trends and uncertainties related to our two business
platforms are as follows:
UnitedHealthcare. We have expanded benefit coverage in areas such as COVID-19 care and testing,
telemedicine, and pharmacy benefits; provided customers assistance in the form of co-pay waivers and premium
forgiveness; offered additional enrollment opportunities to those who previously declined employer-sponsored
offerings; extended certain premium payment terms for customers experiencing financial hardship; simplified
administrative practices; and accelerated payments to care providers, all with the aim of assisting our customers,
17

-- 19 of 32 --

providers and members in addressing the COVID-19 crisis. Temporary care deferrals significantly impacted
UnitedHealthcare’s results of operations for the nine months ended September 30, 2020, contributing to a lower
medical care ratio and higher operating earnings than in previous periods. For the three months ended
September 30, 2020, the impact of temporary care deferrals was more than offset by COVID-19 related care and
testing, the significant financial assistance we continued to provide our customers and broader economic impacts.
Enrollment in our commercial products declined primarily due to employer actions.
Increased consumer demand for care, potentially even higher acuity care, along with continued COVID-19 care
and testing costs are expected to result in increased future medical costs. Disrupted care patterns, as a result of
the pandemic, may temporarily affect the ability to obtain complete member health status information, impacting
future revenue in businesses that utilize risk adjustment methodologies. The ultimate overall impact is uncertain
and dependent on the future pacing and intensity of the pandemic, the duration of policies and initiatives to
address COVID-19, and the progress of an uncertain economic recovery.
Optum. The temporary deferral of care also meaningfully impacted the Optum businesses for the nine months
ended September 30, 2020. For example, our fee-for-service care delivery business, such as traditional procedure
work at our ambulatory surgery centers, was negatively impacted, while our risk-based care delivery business
performance reflected lower demand for care. Our OptumInsight and OptumRx volume-based businesses were
negatively impacted by the lower level of care encounters which took place, as well as by broader economic
factors, contributing to lower managed services and prescription volume. As the health system continues to
return to normal seasonally adjusted levels of care, we have seen business activity approach more normal levels.
COVID-19 will also continue to influence customer and consumer behavior, both during and after the pandemic,
which could impact how care is delivered and the manner in which consumers wish to receive their prescription
drugs or infusion services. The impact of COVID-19 on our care provider and payer clients could impact the
volume and types of services that Optum provides, as well as the pacing of potential new business opportunities.
As a result of the dynamic situation and broad-reaching impact to the health system, the ultimate impact of
COVID-19 on our Optum businesses is uncertain.
Business Trends
Our businesses participate in the United States, South American and certain other international health markets.
Overall spending on health care is impacted by inflation; utilization; medical technology and pharmaceutical
advancement; regulatory requirements; demographic trends in the population; and national interest in health and
well-being. The rate of market growth may be affected by a variety of factors, including macro-economic
conditions, such as the economic impact of COVID-19, and regulatory changes, which could impact our results
of operations, including our continued efforts to control health care costs.
Pricing Trends. To price our health care benefit products, we start with our view of expected future costs,
including any potential impacts from COVID-19 and the Health Insurance Tax. We frequently evaluate and
adjust our approach in each of the local markets we serve, considering all relevant factors, such as product
positioning, price competitiveness and environmental, competitive, legislative and regulatory considerations,
including minimum medical loss ratio (MLR) thresholds. We will continue seeking to balance growth and
profitability across all these dimensions.
The commercial risk market remains highly competitive in both the small group and large group segments. We
expect broad-based competition to continue as the industry adapts to individual and employer needs amid reform
changes. Pricing for contracts that cover some portion of calendar year 2021 will reflect the permanent repeal of
the Health Insurance Tax.
Government programs in the public and senior sector tend to receive lower rates of increase than the commercial
market due to governmental budget pressures and lower cost trends.
18

-- 20 of 32 --

Medical Cost Trends. Our medical cost trends primarily relate to changes in unit costs, health system utilization
and prescription drug costs. COVID-19 care and testing costs and certain of our customer assistance initiatives
have also impacted medical cost trends in the current year and may continue in future years. We endeavor to
mitigate those increases by engaging physicians and consumers with information and helping them make
clinically sound choices, with the objective of helping them achieve high quality, affordable care. The uncertain
impact of COVID-19 may impact our ability to estimate medical costs payable, which could result in increased
variability to medical cost reserve development in future periods.
Regulatory Trends and Uncertainties
Following is a summary of management’s view of regulatory trends and uncertainties. For additional information
regarding regulatory trends and uncertainties, see Part I, Item 1 “Business—Government Regulation,” Part 1,
Item 1A, “Risk Factors,” Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and
Results of Operations” in our 2019 10-K and “Risk Factors” in Part II, Item 1A of this report.
Medicare Advantage Rates. Final 2021 Medicare Advantage rates resulted in an increase in industry base rates
of approximately 1.7%, short of the industry forward medical cost trend, creating continued pressure in the
Medicare Advantage program.
Affordable Care Act (ACA) Tax. After a moratorium in 2019, the industry-wide amount of the Health Insurance
Tax for 2020, which is primarily borne by customers, is $15.5 billion, with our portion being approximately
$3.0 billion. The return of the tax impacts year-over-year comparability of our financial statements, including
revenues, operating costs, medical care ratio (MCR), operating cost ratio, effective tax rate and cash flows from
operations. The ACA Tax was permanently repealed by Congress, effective January 1, 2021.
SELECTED OPERATING PERFORMANCE AND OTHER SIGNIFICANT ITEMS
The following summarizes select third quarter 2020 year-over-year operating comparisons to third quarter 2019,
which were significantly impacted by the effects of COVID-19 on the health system.
• 	Consolidated revenues grew 8%, UnitedHealthcare revenues grew 5% and Optum revenues grew 21%.
• 	UnitedHealthcare served 635,000 fewer people domestically primarily due to increased unemployment and
expected attrition in commercial group benefits.
• 	Consolidated earnings from operations decreased 7%, including a decrease of 22% at UnitedHealthcare
primarily due to COVID-19 impacts, partially offset by an increase of 9% at Optum.
• 	Diluted earnings per common share decreased to $3.30.
• 	Cash flows from operations for the nine months ended September 30, 2020 were $16.1 billion.
• 	Return on equity was 19.7%.
19

-- 21 of 32 --

RESULTS SUMMARY
The following table summarizes our consolidated results of operations and other financial information:
(in millions, except percentages and per share
data)
Three Months Ended
September 30, Increase/
(Decrease) Nine Months Ended
September 30, Increase/
(Decrease)
2020 	2019 	2020 vs. 2019 	2020 	2019 	2020 vs. 2019
Revenues:
Premiums . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 50,863 	$ 47,397 	$ 3,466 	7% $ 150,897 	$ 142,074 	$ 8,823 	6%
Products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	8,777 	7,546 	1,231 	16 	25,455 	23,971 	1,484 	6
Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	5,124 	4,942 	182 	4 	14,265 	13,756 	509 	4
Investment and other income . . . . . . . . . . . . . 	351 	466 	(115) 	(25) 	1,057 	1,453 	(396) 	(27)
Total revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	65,115 	60,351 	4,764 	8 	191,674 	181,254 	10,420 	6
Operating costs:
Medical costs . . . . . . . . . . . . . . . . . . . . . . . . . 	41,636 	39,041 	2,595 	7 	117,314 	117,164 	150 	—
Operating costs . . . . . . . . . . . . . . . . . . . . . . . . 	10,174 	8,960 	1,214 	14 	30,190 	25,892 	4,298 	17
Cost of products sold . . . . . . . . . . . . . . . . . . . 	7,935 	6,627 	1,308 	20 	23,123 	21,606 	1,517 	7
Depreciation and amortization . . . . . . . . . . . . 	719 	709 	10 	1 	2,159 	2,002 	157 	8
Total operating costs . . . . . . . . . . . . . . . . . . . . . . . . 	60,464 	55,337 	5,127 	9 	172,786 	166,664 	6,122 	4
Earnings from operations . . . . . . . . . . . . . . . . . . . . 	4,651 	5,014 	(363) 	(7) 	18,888 	14,590 	4,298 	29
Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(395) 	(449) 	54 	(12) 	(1,262) 	(1,267) 	5 	—
Earnings before income taxes . . . . . . . . . . . . . . . . . 	4,256 	4,565 	(309) 	(7) 	17,626 	13,323 	4,303 	32
Provision for income taxes . . . . . . . . . . . . . . . . . . . 	(1,000) 	(936) 	(64) 	7 	(4,209) 	(2,752) 	(1,457) 	53
Net earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3,256 	3,629 	(373) 	(10) 	13,417 	10,571 	2,846 	27
Earnings attributable to noncontrolling interests . . 	(84) 	(91) 	7 	(8) 	(226) 	(273) 	47 	(17)
Net earnings attributable to UnitedHealth Group
common shareholders . . . . . . . . . . . . . . . . . . . . . 	$ 3,172 	$ 3,538 	$ (366) 	(10)% $ 13,191 	$ 10,298 	$ 2,893 	28%
Diluted earnings per share attributable to
UnitedHealth Group common shareholders . . . . 	$ 	3.30 	$ 	3.67 	$ (0.37) 	(10)% $ 	13.73 	$ 	10.65 	$ 	3.08 	29%
Medical care ratio (a) . . . . . . . . . . . . . . . . . . . . . . . 	81.9% 	82.4% 	(0.5)% 	77.7% 	82.5% 	(4.8)%
Operating cost ratio . . . . . . . . . . . . . . . . . . . . . . . . . 	15.6 	14.8 	0.8 	15.8 	14.3 	1.5
Operating margin . . . . . . . . . . . . . . . . . . . . . . . . . . 	7.1 	8.3 	(1.2) 	9.9 	8.0 	1.9
Tax rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	23.5 	20.5 	3.0 	23.9 	20.7 	3.2
Net earnings margin (b) . . . . . . . . . . . . . . . . . . . . . 	4.9 	5.9 	(1.0) 	6.9 	5.7 	1.2
Return on equity (c) . . . . . . . . . . . . . . . . . . . . . . . . 	19.7% 	26.2% 	(6.5)% 	28.9% 	26.0% 	2.9%
(a) Medical care ratio is calculated as medical costs divided by premium revenue.
(b) Net earnings margin attributable to UnitedHealth Group shareholders.
(c) Return on equity is calculated as annualized net earnings attributable to UnitedHealth Group common shareholders divided by average
shareholders’ equity. Average shareholders’ equity is calculated using the shareholders’ equity balance at the end of the preceding year
and the shareholders’ equity balances at the end of each of the quarters in the year presented.
2020 RESULTS OF OPERATIONS COMPARED TO 2019 RESULTS OF OPERATIONS
Consolidated Financial Results
Revenue
The increases in revenue were primarily driven by the increase in the number of individuals served through
Medicare Advantage and Medicaid; pricing trends; and organic and acquisition growth across the Optum
business, primarily due to expansion in pharmacy care services and care delivery. The increases were partially
offset by decreased individuals served through our commercial and Global benefits businesses and certain
customer assistance programs. For the nine months ended September 30, 2020, revenues were also negatively
impacted by decreases in our fee-for-service care delivery and other volume-based businesses, primarily as a
result of the impacts of COVID-19 on the economy.
Medical Costs and MCR
Medical costs increased as a result of growth in people served through Medicare Advantage and Medicaid,
medical cost trends and COVID-19 care and testing costs, partially offset by decreased people served in
20

-- 22 of 32 --

commercial and Global and modestly lower care patterns. For the nine months ended September 30, 2020, the
MCR decreased primarily due to the temporary deferral of care and the revenue effects of the return of the Health
Insurance Tax, partially offset by COVID-19 care and testing costs and customer assistance measures.
Operating Cost Ratio
The operating cost ratio increased primarily due to the impact of the return of the Health Insurance Tax and
business mix.
Income Tax Rate
Our effective tax rate increased primarily due to the impact of the return of the nondeductible Health Insurance
Tax.
Reportable Segments
See Note 8 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report for
more information on our segments. We utilize various metrics to evaluate and manage our reportable segments,
including individuals served by UnitedHealthcare by major market segment and funding arrangement, people
served by OptumHealth and adjusted scripts for OptumRx. These metrics are the main drivers of revenue, earnings
and cash flows at each business. The metrics also allow management and investors to evaluate and understand
business mix, customer penetration and pricing trends when comparing the metrics to revenue by segment.
The following table presents a summary of the reportable segment financial information:
Three Months Ended
September 30, Increase/
(Decrease) Nine Months Ended
September 30, Increase/
(Decrease)
(in millions, except percentages) 	2020 	2019 	2020 vs. 2019 	2020 	2019 	2020 vs. 2019
Revenues
UnitedHealthcare . . . . . . . . . . . . . . . . . . . . . 	$ 50,373 	$ 48,105 	$ 2,268 	5% $150,548 	$145,595 	$ 4,953 	3%
OptumHealth . . . . . . . . . . . . . . . . . . . . 	10,499 	8,133 	2,366 	29 	28,830 	21,994 	6,836 	31
OptumInsight . . . . . . . . . . . . . . . . . . . . 	2,767 	2,617 	150 	6 	7,893 	7,145 	748 	10
OptumRx . . . . . . . . . . . . . . . . . . . . . . . 	22,081 	18,454 	3,627 	20 	65,009 	55,194 	9,815 	18
Optum eliminations . . . . . . . . . . . . . . . 	(424) 	(441) 	17 	(4) 	(1,275) 	(1,181) 	(94) 	8
Optum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	34,923 	28,763 	6,160 	21 	100,457 	83,152 	17,305 	21
Eliminations . . . . . . . . . . . . . . . . . . . . . . . . . 	(20,181) 	(16,517) 	(3,664) 	22 	(59,331) 	(47,493) 	(11,838) 	25
Consolidated revenues . . . . . . . . . . . . . . . . . 	$ 65,115 	$ 60,351 	$ 4,764 	8% $191,674 	$181,254 	$ 10,420 	6%
Earnings from operations
UnitedHealthcare . . . . . . . . . . . . . . . . . . . . . 	$ 2,068 	$ 2,655 	$ (587) (22)% $ 11,963 	$ 	8,251 	$ 3,712 	45%
OptumHealth . . . . . . . . . . . . . . . . . . . . 	835 	748 	87 	12 	2,388 	2,062 	326 	16
OptumInsight . . . . . . . . . . . . . . . . . . . . 	785 	632 	153 	24 	1,882 	1,589 	293 	18
OptumRx . . . . . . . . . . . . . . . . . . . . . . . 	963 	979 	(16) 	(2) 	2,655 	2,688 	(33) 	(1)
Optum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,583 	2,359 	224 	9 	6,925 	6,339 	586 	9
Consolidated earnings from operations . . . . 	$ 4,651 	$ 5,014 	$ (363) 	(7)% $ 18,888 	$ 14,590 	$ 4,298 	29%
Operating margin
UnitedHealthcare . . . . . . . . . . . . . . . . . . . . . 	4.1% 	5.5% 	(1.4)% 	7.9% 	5.7% 	2.2%
OptumHealth . . . . . . . . . . . . . . . . . . . . 	8.0 	9.2 	(1.2) 	8.3 	9.4 	(1.1)
OptumInsight . . . . . . . . . . . . . . . . . . . . 	28.4 	24.1 	4.3 	23.8 	22.2 	1.6
OptumRx . . . . . . . . . . . . . . . . . . . . . . . 	4.4 	5.3 	(0.9) 	4.1 	4.9 	(0.8)
Optum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	7.4 	8.2 	(0.8) 	6.9 	7.6 	(0.7)
Consolidated operating margin . . . . . . . . . . 	7.1% 	8.3% 	(1.2)% 	9.9% 	8.0% 	1.9%
21

-- 23 of 32 --

UnitedHealthcare
The following table summarizes UnitedHealthcare revenues by business:
Three Months Ended
September 30, Increase/
(Decrease) Nine Months Ended
September 30, Increase/
(Decrease)
(in millions, except percentages) 	2020 	2019 	2020 vs. 2019 	2020 	2019 	2020 vs. 2019
UnitedHealthcare Employer &
Individual . . . . . . . . . . . . . . . . . . . . . . . . 	$14,081 	$14,291 	$ (210) 	(1)% $ 41,324 	$ 42,407 	$(1,083) 	(3)%
UnitedHealthcare Medicare &
Retirement . . . . . . . . . . . . . . . . . . . . . . . 	22,606 	20,698 	1,908 	9 	68,613 	62,649 	5,964 	10
UnitedHealthcare Community & State . . . 	11,820 	10,670 	1,150 	11 	34,796 	33,038 	1,758 	5
UnitedHealthcare Global . . . . . . . . . . . . . . 	1,866 	2,446 	(580) (24) 	5,815 	7,501 	(1,686) (22)
Total UnitedHealthcare revenues . . . 	$50,373 	$48,105 	$ 2,268 	5% 	$150,548 	$145,595 	$ 4,953 	3%
The following table summarizes the number of individuals served by our UnitedHealthcare businesses, by major
market segment and funding arrangement:
September 30, Increase/
(Decrease)
(in thousands, except percentages) 	2020 	2019 	2020 vs. 2019
Commercial:
Risk-based . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	7,950 	8,605 	(655) 	(8)%
Fee-based . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	18,400 	19,230 	(830) 	(4)
Total commercial . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	26,350 	27,835 	(1,485) 	(5)
Medicare Advantage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	5,670 	5,230 	440 	8
Medicaid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6,435 	5,965 	470 	8
Medicare Supplement (Standardized) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,450 	4,510 	(60) 	(1)
Total public and senior . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	16,555 	15,705 	850 	5
Total UnitedHealthcare—domestic medical . . . . . . . . . . . . . . . . . . . . . . . . . . . 	42,905 	43,540 	(635) 	(1)
Global . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	5,285 	5,845 	(560) (10)
Total UnitedHealthcare—medical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	48,190 	49,385 	(1,195) 	(2)%
Supplemental Data:
Medicare Part D stand-alone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,075 	4,415 	(340) 	(8)%
Fee-based and risk-based commercial business decreased primarily due to increased unemployment and expected
attrition. Medicare Advantage increased due to growth in people served through individual Medicare Advantage
plans. The increase in people served through Medicaid was primarily driven by states easing redetermination
requirements due to COVID-19 and growth in people served via Dual Special Needs Plans. The decrease in
people served by UnitedHealthcare Global is a result of our continued affordability efforts, underwriting
discipline and increased unemployment.
UnitedHealthcare’s revenue increased due to growth in the number of individuals served through Medicare
Advantage and Medicaid, a greater mix of people with higher acuity needs and the return of the Health Insurance
Tax, partially offset by a decrease in the number of individuals served through the commercial and Global
businesses and foreign currency impacts. For the three months ended September 30, 2020, earnings from
operations decreased due to direct COVID-19 care and testing costs, our customer assistance measures as well as
broader economic effects, partially offset by modestly lower care patterns. For the nine months ended
September 30, 2020, earnings from operations increased due to the deferral of care caused by COVID-19 on the
health system and the factors impacting revenue, partially offset by the return of the Health Insurance Tax,
COVID-19 care and testing costs, customer assistance programs and broader economic effects.
22

-- 24 of 32 --

Optum
Total revenues increased as each segment reported revenue growth. Earnings from operations increased due to
growth at OptumHealth and OptumInsight.
The results by segment were as follows:
OptumHealth
Revenue and earnings at OptumHealth increased primarily due to organic growth and acquisitions in risk-based
care delivery. For the nine months ended September 30, 2020, reduced care volumes in fee-for-service
arrangements as a result of COVID-19, partially offset the increases in revenues and earnings. OptumHealth
served approximately 98 million people as of September 30, 2020 compared to 95 million people as of
September 30, 2019.
OptumInsight
Revenue and earnings from operations at OptumInsight increased primarily due to growth in technology and
managed services, partially offset by decreased activity levels in volume-based services due to the impact of
COVID-19 on payer and care provider clients.
OptumRx
Revenue at OptumRx and the corresponding eliminations increased due to the inclusion of retail pharmacy
co-payments. See Note 1 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1
of this report for further detail. Revenue at OptumRx also increased due to organic and acquisition growth in
specialty pharmacy and new client wins, partially offset by an expected large client transition and lower script
volumes driven by COVID-19 related care deferral, primarily related to first fill script volumes. Earnings from
operations decreased primarily due to COVID-19 impacts, partially offset by improved supply chain
management. OptumRx fulfilled 325 million adjusted scripts in both the third quarters of 2020 and 2019, with
growth offset by the large client transition.
23

-- 25 of 32 --

LIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCES
Liquidity
Summary of our Major Sources and Uses of Cash and Cash Equivalents
Nine Months Ended
September 30, Increase/
(Decrease)
(in millions) 	2020 	2019 	2020 vs. 2019
Sources of cash:
Cash provided by operating activities . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 16,073 	$ 12,258 	$ 	3,815
Issuances of short-term borrowings and long-term debt, net of
repayments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,941 	8,192 	(5,251)
Proceeds from common stock issuances . . . . . . . . . . . . . . . . . . . . . . . . . 	1,206 	740 	466
Customer funds administered . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	249 	420 	(171)
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	— 	338 	(338)
Total sources of cash . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	20,469 	21,948
Uses of cash:
Common stock repurchases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(2,541) 	(5,101) 	2,560
Cash paid for acquisitions, net of cash assumed . . . . . . . . . . . . . . . . . . . 	(4,326) 	(8,200) 	3,874
Purchases of investments, net of sales and maturities . . . . . . . . . . . . . . . 	(1,386) 	(2,028) 	642
Purchases of property, equipment and capitalized software . . . . . . . . . . 	(1,477) 	(1,421) 	(56)
Cash dividends paid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(3,400) 	(2,908) 	(492)
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(614) 	(756) 	142
Total uses of cash . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(13,744) 	(20,414)
Effect of exchange rate changes on cash and cash equivalents . . . . . . . . . . . . 	(160) 	(37) 	(123)
Net increase in cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	6,565 	$ 	1,497 	$ 	5,068
2020 Cash Flows Compared to 2019 Cash Flows
Increased cash flows provided by operating activities were primarily driven by increased net earnings as a result
of the temporary deferral of care experienced at our benefits businesses related to COVID-19, partially offset by
the payment of the Health Insurance Tax in the third quarter. Other significant changes in sources or uses of cash
year-over-year included decreased cash paid for acquisitions, common stock repurchases and net purchases of
investments, partially offset by decreased issuances of long-term debt.
Financial Condition
As of September 30, 2020, our cash, cash equivalent, available-for-sale debt securities and equity securities
balances of $58.0 billion included approximately $17.6 billion of cash and cash equivalents (of which
$2.9 billion was available for general corporate use), $38.3 billion of debt securities and $2.1 billion of
investments in equity securities. Given the significant portion of our portfolio held in cash and cash equivalents,
we do not anticipate fluctuations in the aggregate fair value of our financial assets to have a material impact on
our liquidity or capital position. Our available-for-sale debt portfolio had a weighted-average duration of 3.6
years and a weighted-average credit rating of “Double A” as of September 30, 2020. When multiple credit ratings
are available for an individual security, the average of the available ratings is used to determine the weighted-
average credit rating.
24

-- 26 of 32 --

Capital Resources and Uses of Liquidity
In addition to cash flows from operations and cash and cash equivalent balances available for general corporate
use, our capital resources and uses of liquidity are as follows:
Commercial Paper and Bank Credit Facilities. Our revolving bank credit facilities provide liquidity support for
our commercial paper borrowing program, which facilitates the private placement of unsecured debt through
independent broker-dealers, and are available for general corporate purposes. For more information on our
commercial paper and bank credit facilities, see Note 5 of Notes to the Condensed Consolidated Financial
Statements included in Part I, Item 1 of this report.
Our revolving bank credit facilities contain various covenants, including covenants requiring us to maintain a
defined debt to debt-plus-shareholders’ equity ratio of not more than 60%. As of September 30, 2020, our debt to
debt-plus-shareholders’ equity ratio, as defined and calculated under the credit facilities, was approximately 38%.
Long-Term Debt. Periodically, we access capital markets and issue long-term debt for general corporate
purposes, such as, to meet our working capital requirements, to refinance debt, to finance acquisitions or for
share repurchases. For more information on our long-term debt, see Note 5 of Notes to the Condensed
Consolidated Financial Statements included in Part I, Item 1 of this report.
Credit Ratings. Our credit ratings as of September 30, 2020 were as follows:
Moody’s 	S&P Global 	Fitch 	A.M. Best
Ratings 	Outlook 	Ratings 	Outlook 	Ratings 	Outlook 	Ratings 	Outlook
Senior unsecured debt . . . . . . . . . . . . 	A3 	Stable 	A+ 	Stable 	A 	Stable 	A- 	Positive
Commercial paper . . . . . . . . . . . . . . . 	P-2 	n/a 	A-1 	n/a 	F1 	n/a 	AMB-1 	n/a
The availability of financing in the form of debt or equity is influenced by many factors, including our
profitability, operating cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions,
regulatory requirements and economic and market conditions, including the impacts of COVID-19 and related
governmental market stabilization programs. A significant downgrade in our credit ratings or adverse conditions
in the capital markets may increase the cost of borrowing for us or limit our access to capital.
Share Repurchase Program. During the nine months ended September 30, 2020, we repurchased 9 million
shares at an average price of $281.37 per share. As of September 30, 2020, we had Board authorization to
purchase up to 63 million shares of our common stock.
Dividends. In June 2020, the Company’s Board of Directors increased the Company’s quarterly cash dividend to
shareholders to an annual rate of $5.00 compared to $4.32 per share. For more information on our dividend, see
Note 6 of Notes to the Condensed Consolidated Financial Statements included in Part 1, Item 1 of this report.
For additional liquidity discussion, see Note 10 of Notes to the Consolidated Financial Statements in Part II, Item
8, “Financial Statements and Supplementary Data” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” in Part II, Item 7 in our 2019 10-K.
CONTRACTUAL OBLIGATIONS AND COMMITMENTS
A summary of future obligations under our various contractual obligations and commitments as of December 31,
2019 was disclosed in our 2019 10-K. During the nine months ended September 30, 2020, there were no material
changes to this previously disclosed information outside the ordinary course of business. However, we
continually evaluate opportunities to expand our operations, including through internal development of new
products, programs and technology applications and acquisitions.
25

-- 27 of 32 --

RECENTLY ISSUED ACCOUNTING STANDARDS
See Note 1 of Notes to the Condensed Consolidated Financial Statements in Part I, Item 1 of this report for a
discussion of new accounting pronouncements that affect us.
CRITICAL ACCOUNTING ESTIMATES
In preparing our Condensed Consolidated Financial Statements, we are required to make judgments, assumptions
and estimates, which we believe are reasonable and prudent based on the available facts and circumstances.
These judgments, assumptions and estimates affect certain of our revenues and expenses and their related balance
sheet accounts and disclosure of our contingent liabilities. We base our assumptions and estimates primarily on
historical experience and consider known and projected trends. On an ongoing basis, we re-evaluate our selection
of assumptions and the method of calculating our estimates. Actual results, however, may materially differ from
our calculated estimates, and this difference would be reported in our current operations.
Our critical accounting estimates include medical costs payable and goodwill. For a detailed description of our
critical accounting estimates, see “Management’s Discussion and Analysis of Financial Condition and Results of
Operations” in Part II, Item 7 in our 2019 10-K. For a detailed discussion of our significant accounting policies,
see Note 2 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements and
Supplementary Data” in our 2019 10-K.
FORWARD-LOOKING STATEMENTS
The statements, estimates, projections, guidance or outlook contained in this document include “forward-
looking” statements which are intended to take advantage of the “safe harbor” provisions of the federal securities
law. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “forecast,” “outlook,” “plan,” “project,”
“should” and similar expressions identify forward-looking statements. These statements may contain information
about financial prospects, economic conditions and trends and involve risks and uncertainties. Actual results
could differ materially from those that management expects, depending on the outcome of certain factors
including: risks associated with public health crises, large-scale medical emergencies and pandemics, such as the
COVID-19 pandemic; our ability to effectively estimate, price for and manage medical costs; new or changes in
existing health care laws or regulations, or their enforcement or application; the DOJ’s legal action relating to the
risk adjustment submission matter; our ability to maintain and achieve improvement in quality scores impacting
revenue; reductions in revenue or delays to cash flows received under government programs; changes in
Medicare, the CMS star ratings program or the application of risk adjustment data validation audits; failure to
maintain effective and efficient information systems or if our technology products do not operate as intended;
cyber-attacks, other privacy/data security incidents, or our failure to comply with related regulations; risks and
uncertainties associated with the pharmacy benefits management industry; competitive pressures; changes in or
challenges to our public sector contract awards; our ability to contract on competitive terms with physicians,
hospitals and other service providers; failure to achieve targeted operating cost productivity improvements;
increases in costs and other liabilities associated with litigation, government investigations, audits or reviews;
failure to manage successfully our strategic alliances or complete or receive anticipated benefits of strategic
transactions; fluctuations in foreign currency exchange rates; downgrades in our credit ratings; our investment
portfolio performance; impairment of our goodwill and intangible assets; and our ability to obtain sufficient
funds from our regulated subsidiaries or from external financings to fund our obligations, maintain our debt to
total capital ratio at targeted levels, maintain our quarterly dividend payment cycle, or continue repurchasing
shares of our common stock. This above list is not exhaustive. We discuss these matters, and certain risks that
may affect our business operations, financial condition and results of operations more fully in our filings with the
SEC, including our reports on Forms 10-K, 10-Q and 8-K. By their nature, forward-looking statements are not
guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are
difficult to predict or quantify. Actual results may vary materially from expectations expressed or implied in this
document or any of our prior communications. You should not place undue reliance on forward-looking
statements, which speak only as of the date they are made. We do not undertake to update or revise any forward-
looking statements, except as required by law.
26

-- 28 of 32 --

ITEM 3. 	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We manage exposure to market interest rates by diversifying investments across different fixed-income market
sectors and debt across maturities, as well as by endeavoring to match our floating-rate assets and liabilities over
time, either directly or through the use of interest rate swap contracts. Unrealized gains and losses on investments
in available-for-sale debt securities are reported in comprehensive income.
The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield
curve by 1% point or 2% points as of September 30, 2020 on our investment income and interest expense per
annum, and the fair value of our investments and debt (in millions, except percentages):
September 30, 2020
Increase (Decrease) in Market Interest Rate
Investment
Income Per
Annum (a)
Interest
Expense Per
Annum (a)
Fair Value of
Financial
Assets (b)
Fair Value of
Financial
Liabilities
2% . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	412 	$ 	176 	$ (2,847) 	$ (8,464)
1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	206 	88 	(1,412) 	(4,609)
(1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(62) 	(13) 	636 	4,792
(2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(62) 	(13) 	675 	6,424
(a) 	Given the low absolute level of short-term market rates on our floating-rate assets and liabilities as of
September 30, 2020, the assumed hypothetical change in interest rates does not reflect the full 100 and 200
basis point reduction in interest income or interest expense, as the rates are assumed not to fall below zero.
(b) 	As of September 30, 2020, some of our investments had interest rates below 1% so the assumed
hypothetical change in the fair value of investments does not reflect the full 100 and 200 basis point
reduction.
ITEM 4. 	CONTROLS AND PROCEDURES
EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES
We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities
Exchange Act of 1934 (Exchange Act) that are designed to provide reasonable assurance that information
required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed,
summarized and reported within the time periods specified in SEC rules and forms; and (ii) accumulated and
communicated to our management, including our principal executive officer and principal financial officer, as
appropriate to allow timely decisions regarding required disclosure.
In connection with the filing of this quarterly report on Form 10-Q, management evaluated, under the supervision
and with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the
design and operation of our disclosure controls and procedures as of September 30, 2020. Based upon that
evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and
procedures were effective at the reasonable assurance level as of September 30, 2020.
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
There have been no changes in our internal control over financial reporting during the quarter ended
September 30, 2020 that have materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.
27

-- 29 of 32 --

PART II. OTHER INFORMATION
ITEM 1. 	LEGAL PROCEEDINGS
A description of our legal proceedings is included in and incorporated by reference to Note 7 of Notes to the
Condensed Consolidated Financial Statements contained in Part I, Item 1 of this report.
ITEM 1A. RISK FACTORS
In addition to the other information set forth in this report, you should carefully consider the factors discussed in
Part I, Item 1A, “Risk Factors” of our 2019 10-K and Part II, Item 1A, “Risk Factors” of our 10-Q for the
quarterly period ended March 31, 2020 (“2020 First Quarter 10-Q”), which could materially affect our business,
financial condition or future results. The risks described in our 2019 10-K and 2020 First Quarter 10-Q, are not
the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to
be immaterial also may materially adversely affect our business, financial condition or future results.
There have been no other material changes to the risk factors as disclosed in our 2019 10-K and 2020 First
Quarter 10-Q.
ITEM 2. 	UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS
In November 1997, our Board of Directors adopted a share repurchase program, which the Board evaluates
periodically. There is no established expiration date for the program. During the third quarter 2020, we
repurchased approximately 3 million shares at an average price of $303.76 per share. As of September 30, 2020,
we had Board authorization to purchase up to 63 million shares of our common stock.
28

-- 30 of 32 --

ITEM 6. 	EXHIBITS*
The following exhibits are filed or incorporated by reference herein in response to Item 601 of Regulation S-K.
The Company files Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on
Form 8-K pursuant to the Securities Exchange Act of 1934 under Commission File No. 1-10864.
3.1 	Certificate of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to
Exhibit 3.1 to the Company’s Registration Statement on Form 8-A/A filed on July 1, 2015)
3.2 	Bylaws of UnitedHealth Group Incorporated, effective August 15, 2017 (incorporated by reference to
Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on August 16, 2017)
4.1 	Senior Indenture, dated as of November 15, 1998, between United HealthCare Corporation and The
Bank of New York (incorporated by reference to Exhibit 4.1 to the Company’s Registration
Statement on Form S-3/A, SEC File Number 333-66013, filed on January 11, 1999)
4.2 	Amendment, dated as of November 6, 2000, to Senior Indenture, dated as of November 15, 1998,
between UnitedHealth Group Incorporated and The Bank of New York (incorporated by reference to
Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30,
2001)
4.3 	Instrument of Resignation, Appointment and Acceptance of Trustee, dated January 8, 2007, pursuant
to the Senior Indenture, dated as of November 15, 1998, amended November 6, 2000, among
UnitedHealth Group Incorporated, The Bank of New York and Wilmington Trust Company
(incorporated by reference to Exhibit 4.3 to the Company’s Quarterly Report on Form 10-Q for the
quarter ended June 30, 2007)
4.4 	Indenture, dated as of February 4, 2008, between UnitedHealth Group Incorporated and U.S. Bank
National Association (incorporated by reference to Exhibit 4.1 to the Company’s Registration
Statement on Form S-3, SEC File Number 333-149031, filed on February 4, 2008)
31.1 	Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 	Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS 	XBRL Instance Document—the instance document does not appear in the Interactive Data File
because its XBRL tags are embedded within the Inline XBRL document.
101.SCH 	Inline XBRL Taxonomy Extension Schema Document.
101.CAL 	Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF 	Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB 	Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE 	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104 	Cover Page Interactive Data File (formatted as Inline XBRL and embedded within Exhibit 101).
* 	Pursuant to Item 601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain
holders of long-term debt are not filed. The Company will furnish copies thereof to the SEC upon request.
29

-- 31 of 32 --

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.
UNITEDHEALTH GROUP INCORPORATED
/s/ 	DAVID S. WICHMANN 	Chief Executive Officer
(principal executive officer) Dated: 	November 2, 2020
David S. Wichmann
/s/ 	JOHN F. REX
Executive Vice President and
Chief Financial Officer
(principal financial officer) Dated: 	November 2, 2020
John F. Rex
/s/ 	THOMAS E. ROOS
Senior Vice President and
Chief Accounting Officer
(principal accounting officer) Dated: 	November 2, 2020
Thomas E. Roos
30

-- 32 of 32 --